GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Shiller PE Ratio

Medivir AB (Medivir AB) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medivir AB Shiller PE Ratio Historical Data

The historical data trend for Medivir AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Shiller PE Ratio Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.51 4.45 10.19 5.64 2.03

Medivir AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.64 5.42 3.93 3.86 2.03

Competitive Comparison of Medivir AB's Shiller PE Ratio

For the Biotechnology subindustry, Medivir AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Shiller PE Ratio falls into.



Medivir AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Medivir AB's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Medivir AB's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/130.9575*130.9575
=0.000

Current CPI (Dec. 2023) = 130.9575.

Medivir AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 1.154 99.788 1.514
201406 2.356 100.432 3.072
201409 1.362 100.161 1.781
201412 0.505 100.225 0.660
201503 0.218 99.950 0.286
201506 0.218 99.995 0.286
201509 -0.035 100.228 -0.046
201512 -0.150 100.276 -0.196
201603 -0.148 100.751 -0.192
201606 -0.146 101.019 -0.189
201609 -0.180 101.138 -0.233
201612 1.366 102.022 1.753
201703 -0.331 102.022 -0.425
201706 -0.370 102.752 -0.472
201709 -0.404 103.279 -0.512
201712 -0.487 103.793 -0.614
201803 -0.316 103.962 -0.398
201806 -0.352 104.875 -0.440
201809 -0.269 105.679 -0.333
201812 -0.431 105.912 -0.533
201903 -0.203 105.886 -0.251
201906 -0.045 106.742 -0.055
201909 -0.080 107.214 -0.098
201912 -0.115 107.766 -0.140
202003 -0.098 106.563 -0.120
202006 -0.056 107.498 -0.068
202009 0.021 107.635 0.026
202012 -0.045 108.296 -0.054
202103 -0.021 108.360 -0.025
202106 -0.037 108.928 -0.044
202109 -0.028 110.338 -0.033
202112 -0.050 112.486 -0.058
202203 -0.062 114.825 -0.071
202206 -0.042 118.384 -0.046
202209 -0.025 122.296 -0.027
202212 -0.031 126.365 -0.032
202303 -0.032 127.042 -0.033
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 130.958 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medivir AB  (OTCPK:MVRBF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Medivir AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Medivir AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (Medivir AB) Business Description

Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.